LEADER 03962nam  22005895  450 
001 9910300342803321
005 20200702141949.0
010   $a1-4471-6503-9
024 7 $a10.1007/978-1-4471-6503-3
035   $a(CKB)3710000000261222
035   $a(EBL)1964768
035   $a(OCoLC)893426429
035   $a(SSID)ssj0001372684
035   $a(PQKBManifestationID)11734869
035   $a(PQKBTitleCode)TC0001372684
035   $a(PQKBWorkID)11312060
035   $a(PQKB)10017516
035   $a(MiAaPQ)EBC1964768
035   $a(DE-He213)978-1-4471-6503-3
035   $a(PPN)182092917
035   $a(EXLCZ)993710000000261222
100   $a20141008d2014      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aLevodopa-Induced Dyskinesia in Parkinson's Disease /$fedited by Susan H. Fox, Jonathan M. Brotchie
205   $a1st ed. 2014.
210  1$aLondon :$cSpringer London :$cImprint: Springer,$d2014.
215   $a1 online resource (371 p.)
300   $aDescription based upon print version of record.
311   $a1-4471-6502-0 
320   $aIncludes bibliographical references and index.
327   $aPhenomenology of Levodopa-Induced Dyskinesia -- Dyskinesia Rating Scales in Parkinson's Disease -- Epidemiology of Levodopa-Induced Dyskinesia -- Risk Factors for Levodopa-Induced Dyskinesia -- Pharmacological Treatment Options for Levodopa-Induced Dyskinesia -- Surgical Options for Levodopa-Induced Dyskinesia in Parkinson?s Disease -- Basal Ganglia Circuitry Models of L-DOPA-Induced Dyskinesia -- Basal Ganglia Circuitry Models of L-DOPA-Induced Dyskinesia -- Pharmacological Properties of Levodopa -- Dopamine Receptors and LID -- The Serotonergic System In Levodopa-Induced Dyskinesia -- The Opioid System in Levodopa-Induced Dyskinesia -- Glutamate Receptors and Levodopa-Induced Dyskinesia -- Cannabinoids and Levodopa-Induced Dyskinesia -- The Role of the Noradrenergic System and its Receptors In Levodopa-Induced Dyskinesia -- Involvement of the Cholinergic System in Levodopa-Induced Dyskinesia -- New Clinical Trials for Levodopa-Induced Dyskinesia -- Preclinical Models of Levodopa-Induced Dyskinesia -- Final Thoughts: Summary and Future Therapeutic Strategies in LID.
330   $aThis book aims to provide a single reference source on levodopa-induced dyskinesias (LID) from ?bench to bedside?. Initial chapters review the clinical features and phenomenology of LID with video examples; epidemiology and genetic risk factors for LID are covered as a background to understanding risk factors for developing LID. The following chapters cover the latest preclinical studies aiming to understand the pathophysiology of LID at the cellular, neurochemical, neurophysiological and circuitry level with detailed discussion of mechanisms and future directions to take the field forward; clinical studies from phase II to phase IV; ongoing RCTs in LID; and evidence-based medicine reviews of treatment options.  Levodopa-Induced Dyskinesia in Parkinson?s Disease is aimed at an international audience of movement disorder neurologists; neuroscientists; trainees; and graduate and post-graduate students.
606   $aNeurology 
606   $aNeurosciences
606   $aNeurology$3https://scigraph.springernature.com/ontologies/product-market-codes/H36001
606   $aNeurosciences$3https://scigraph.springernature.com/ontologies/product-market-codes/B18006
615  0$aNeurology .
615  0$aNeurosciences.
615 14$aNeurology.
615 24$aNeurosciences.
676   $a616.8
676   $a616.833075
702   $aFox$b Susan H$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aBrotchie$b Jonathan M$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910300342803321
996   $aLevodopa-Induced Dyskinesia in Parkinson's Disease$91521851
997   $aUNINA